TY  - JOUR
AU  - Schuepbach, W. M. Michael
AU  - Tonder, Lisa
AU  - Schnitzler, Alfons
AU  - Krack, Paul
AU  - Rau, Joern
AU  - Hartmann, Andreas
AU  - Hälbig, Thomas
AU  - Pineau, Fanny
AU  - Falk, Andrea
AU  - Paschen, Laura
AU  - Paschen, Stephen
AU  - Volkmann, Jens
AU  - Dafsari, Haidar S.
AU  - Barbe, Michael
AU  - Fink, Gereon R.
AU  - Kühn, Andrea
AU  - Kupsch, Andreas
AU  - Schneider, Gerd-H.
AU  - Seigneuret, Eric
AU  - Fraix, Valerie
AU  - Kistner, Andrea
AU  - Chaynes, P. Patrick
AU  - Ory-Magne, Fabienne
AU  - Brefel-Courbon, Christine
AU  - Vesper, Jan
AU  - Wojtecki, Lars
AU  - Derrey, Stéphane
AU  - Maltête, David
AU  - Damier, Philippe
AU  - Derkinderen, Pascal
AU  - Sixel-Döring, Friederike
AU  - Trenkwalder, Claudia
AU  - Gharabaghi, Alireza
AU  - Wächter, Tobias
AU  - Weiss, Daniel
AU  - Pinsker, Marcus O.
AU  - Regis, Jean-Marie
AU  - Witjas, Tatiana
AU  - Thobois, Stephane
AU  - Mertens, Patrick
AU  - Knudsen, Karina
AU  - Schade-Brittinger, Carmen
AU  - Houeto, Jean-Luc
AU  - Agid, Yves
AU  - Vidailhet, Marie
AU  - Timmermann, Lars
AU  - Deuschl, Günther
TI  - Quality of life predicts outcome of deep brain stimulation in early Parkinson disease
JO  - Neurology
VL  - 92
IS  - 10
SN  - 1526-632X
CY  - [S.l.]
PB  - Ovid
M1  - FZJ-2019-01610
SP  - e1109
PY  - 2019
AB  - Objective To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.Methods We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.Results PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.Conclusion Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.
LB  - PUB:(DE-HGF)16
C6  - pmid:30737338
UR  - <Go to ISI:>//WOS:000463252900018
DO  - DOI:10.1212/WNL.0000000000007037
UR  - https://juser.fz-juelich.de/record/860977
ER  -